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Plain English summary: PLM is an online platform that provides tools for
individuals to track their health and connect with other patients and while PLM has
invited patients to participate in various research projects throughout the years, an
examination into what motivates patients to want to get involved in clinical research
has not been done. During our analysis of applications submitted by members of the
PLM community, we looked for reasons patients want to participate in research and
their overall beliefs about clinical research, in general. In addition, we analyzed
obstacles and barriers toward patients’ research participation. We observed the
following:
 Patients are typically motivated by their individual needs and are most interested
in research specific to their own condition.
 To get the most from patients’ involvement and to enhance patients’ contribution
towards research goals, researchers should explain the research goal and
requirements of each goal in clear and transparent terms, making it easy for patients
to understand, thus avoiding any potential miscommunication.
Future studies are needed to determine the best methods for involving patients in
clinical research.
Background: Historically, throughout the clinical and medical research arenas, patients
have been perceived as passive “subjects” rather than as individuals who may have
thoughts regarding research development, research plans, implementation of research
studies, and data analysis. However, it is becoming more clear that patients increasingly
want to have a more active role in clinical research studies and in the management of
their own medical conditions as evidenced by a “no decision about us without
us” stance, meaning patients want to make informed decisions about their health while
working alongside their healthcare professionals. The central aim of this research study
was to determine patients’ motivations for being involved in research design and
understand their perceptions of current research practices.
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Methods: Two independent qualitative studies were conducted. In Study 1, we
analyzed applications submitted by self-identified patients from within the PatientsLikeMe
(PLM) community, for acceptance onto our advisory panel. The advisory panel was tasked
with developing a best practice guide for how to involve patients in research. During the
qualitative analysis, we identified major reasons for and topics of interest associated with
PLM members’ motivation to apply to the advisory panel. In Study 2, we analyzed
applications from PLM community members and from patients outside the PLM
community for a patient-led patient-reported-outcome (PRO) development project.
Similar to Study 1, we identified themes associated with patients’ motivations to
participate in developing a new PRO.
Results: PLM members are interested in being involved in medical research for
various reasons, including facilitating provider-patient communication, improving
comprehension of medical information, understanding their disease, and bringing a more
individualized approach to health care in general.
Conclusion: Challenges in the process of appropriate involvement of patients in research
are discussed. In both studies, the applicants shared their interests in being involved in
research. However, in Study 2, many of the patients shared ideas that were not appropriate
for the development of a PRO, which indicated limitations in how the invitation and
application explained the project to patients. Future studies should contribute to
determining the most appropriate method for involving patients in various settings.
Keywords: Qualitative research, Patient centeredness, Patient motivation, PRO
development, Patient advocacy, PatientsLikeMe
Background
“E-patients” is a term used by Ferguson to describe patients who are “equipped,
enabled, empowered, and engaged in their own health care” [1]. It is becoming more
often the case that patients living with long-term medical conditions are harnessing
Internet-based technologies, such as social networks, crowdsourcing, and citizen
science, to access the scientific literature, offer peer support, conduct their own
research studies [2], and even develop their own measures to track their health out-
comes [3]. PatientsLikeMe (PLM) is a patient-powered research network comprised of
over 2,500 condition-specific communities that allows patients with life-changing
medical conditions to find other patients with similar conditions, share information
about their outcomes, and actively contribute to research. PLM routinely engages its
patient community by offering the opportunity to participate in surveys and then uses
the data to learn more about these patients and their various conditions. Additionally,
PLM members are encouraged to contribute to ongoing research by sharing data about
their treatments, symptoms, and outcomes on their profile.
Clinical medical research depends on the willingness of patients to volunteer their
time and energy by partaking in experimental interventions, such as clinical trials.
However, the traditional medical research paradigm historically used patients as
“subjects” – uncritical “laypeople” who did what they were told, were unqualified to
provide higher-level input, such as critical appraisal of research methods, and in the
worst cases, were victims of unethical manipulation and the denial of accurate informa-
tion [4]. Even when researchers mean no harm, they often failed to provide study
results to patients and, most definitely, did not view them as a true partner in the
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research process [5]. Medical research has traditionally relied on observable biomarkers
and medical professional-interpreted signs or symptoms to assess treatment effective-
ness or disease progression. However, this model of clinical medical research is chan-
ging, in part due to the decentralized and less hierarchical structure of the Internet as a
means to unite patients with similar conditions and to educate them about their condi-
tion. When these two existing models come into conflict, there is a risk patients may
not want to become involved in clinical research, with consequences for recruitment,
attrition, and protocol violations [5].
The cultures of medicine and research are increasingly recognizing the importance of
patient involvement throughout the research process. For example, regulatory bodies, such
as the FDA, have identified the importance of patient involvement through their patient-
focused drug development program [6]. The Patient Centered Outcomes Research Institute
(PCORI) is one of the largest funders of patient-focused research, with a specific focus on
funding comparative clinical effectiveness research (CER) [7]. PCORI has taken the lead in
ensuring patients are actively involved in research, giving them the opportunity to assume
such roles as peer reviewers of grant proposals, stakeholders in setting policy, and advisors
to ongoing research, allowing patients to stand as empowered peers next to their scientific-
ally- and medically-qualified colleagues [8, 9]. More recently, the focus of medical research
has moved toward patient-reported outcome (PRO) measures, defined by the Food and
Drug Administration (FDA) as “any report of the status of a patient’s health condition that
comes directly from the patient, without interpretation of the patient’s response by a
clinician or anyone else” [8]. Unfortunately, many PRO measures have been developed by
researchers on the basis of what they felt was important to measure rather than what
mattered to patients [9].
Despite enthusiasm for patient-centered healthcare and research, the best methods for
involving patients in the research process has not yet been established [10]. Many factors
need to be addressed and taken into account to ensure the most effective and informative
participation of patients in research, including patients’ lack of familiarity with scientific
and medical terminology [11]. The success of patients’ engagement in research highly
depends on their interest and emotional involvement in the research question and poten-
tial outcomes [10]. Hence, involving patients in the early stages of the research process,
including the development of research questions, becomes a crucial component of
patient-centered research. Indeed, patient involvement in identifying the topics important
for research (topic solicitation) is recognized as an essential first step in CER [12]. This
project addresses the need to involve patients in topic solicitation, investigates associated
barriers and obstacles, and seeks to determine methods to optimize their involvement.
Recognizing the shift towards increased patient involvement in research, PLM estab-
lished a program to facilitate a patient-led research project through the Open Research
Exchange (ORE). ORE, a software platform developed by and integrated with PLM, is an
open platform for developing, validating, and sharing health outcome measures that
determine issues that are important to patients [13, 14]. ORE has been used by academic
and industry researchers in the development of 14 PROs, including measures of treatment
burden [14], medication adherence, and suicidal ideation. Researchers involve patients at
multiple times during development of a PRO on the ORE (e.g. concept elicitation and
soliciting feedback on both individual items and the overall survey) as demonstrated in
the creation of a hypertension management instrument [15].
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The main goal of these studies was to understand patient perspective and motivation for
participating in the development of research study design and policy and also to gain insight
into patient perceptions about and potential barriers to their involvement in clinical re-
search. In Study 1, we solicited applications from patient-members within the PLM
community to join an advisory panel, whose goal was to provide insight and inform PLM
researchers about the patient experience and the needs of patients. The team focused on de-
veloping a “best practice guide” for how to involve patients in research studies. An explora-
tory analysis of the information contained within the applications from patients wanting to
be part of the advisory panel was conducted with the goal of describing the major demo-
graphic and clinical characteristics of patients who applied, reveal the reasons patients were
interested in participating, and determine other motivations for being involved in research.
The goal of Study 2 was to involve patients in developing PRO measurements “from
the ground up” to address the needs of other patients like them. For the purpose of this
study, we conducted an exploratory content analysis of these applications to discover
the key reasons for the patients’ interest in participating in patient-led PRO measure-
ment development. The ultimate goal of these two studies was to learn about patients’
motivation for participating in the research process and to learn about patient expecta-




Patients from within the PLM community who were likely to want to participate in
a research process received an invitation (see Appendix B for invitation language
and application) to join the advisory panel, specifically including those members
who listed ‘Research’ as an interest on their profile, had completed multiple
research surveys, or were known by community moderators through earlier
involvement in other research projects. Prior to the creation of the advisory panel,
members interested in being involved contributed to blogs, videos, or attended
conferences alongside PLM. A private message with a link to the application was
sent through the PLM website (see Appendix B for invitation language). Additionally,
a post in the general PLM forum on the website directed members to the
application. The application had no specific role requirements related to previous
research experience and it was made clear to potential applicants that a broad range
of applicant experience was desired.
Study 2
The participation application was made available to both PLM members and non-PLM
patients through a press release along with a link to the application on the ORE site
(see Appendix C for invitation language and application). Additionally, a post in the
general PatientsLikeMe forum on the main website directed PLM members to the
application. The press release and the open-access post on the PLM blog were freely
republished by other news outlets informing patients about an opportunity to use “your
own and others’ experiences to develop a new health outcome measure that is more
meaningful, helpful and relevant.”
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Procedures
Study 1
Participants had 14 days to respond to the private invitation to join the advisory panel.
Following this period, a shortlist of individuals was selected for a follow-up phone
screen through a two-wave selection process. The criteria used to determine which
patients would receive a follow-up call included that the patient had 1) demonstrated
interest, 2) clear communication skills, and 3) provided a description of their experience.
In addition, PLM researchers conducted one final review of applicants to ensure that a
variety of primary conditions were represented within the sample.
For the purpose of this study, one researcher (MB) completed the exploratory content
analysis of a subsample of applications to reveal the most frequent themes describing
the motivation behind patients’ participation in the advisory panel and in research, in
general. The entire pool of applications was shuffled randomly; applications from both
those who were selected to be on the advisory panel and those who were not selected
were analyzed. Then, the researcher selected the first 20 applications from the entire
pool to review and code, using an inductive approach, and kept selecting the applica-
tions until the saturation of themes regarding motivations was reached, i.e., no new
themes emerged. For each application, we revealed the key motivation to participate in
research and classified the application according to this main theme.
Study 2
Criteria for identifying applicants from within the PLM community and patients from
outside the PLM community to conduct a phone screen for were 1) clarity of communica-
tion, 2) potential for idea to become a patient reported outcome measure, and 3) whether
there were enough members within the PLM community with the medical condition of
interest. There were no specific requirements related to previous experience with research,
condition, and professional background.
For the purpose of this study, one researcher (MB) completed the exploratory content
analysis of all applications for the patient-led project to reveal the most frequent




In total, 5,522 members received the private message invitation; 4,850 of whom,
had indicated ‘Research’ as an interest on their profile and 672, of whom, had taken
multiple surveys. PLM members submitted a total of 482 unsolicited applications.
As a result of the screening process, 84 PLM members were offered phone screens,
of whom, 15 were selected and accepted a position on the panel. The following
primary medical conditions were represented among members of the panel: atten-
tion deficit disorder (ADD), amyotrophic lateral sclerosis (ALS), bipolar II disorder,
epilepsy, Fabry’s disease, fibromyalgia, idiopathic pulmonary fibrosis, major depres-
sive disorder, multiple sclerosis, and Parkinson’s disease. Applicants may have also
had additional comorbidities although these were not included as a factor in the
analyses. A final panel of 14 members (one patient died between acceptance of the
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invitation and the first meeting) was developed. Any applicants not chosen for the
Team of Advisors were invited to be part of a Research Ambassadors program.
The applicants’ ages ranged from 16 to 84 years (mean 53.05 years [SD = 12.33 years]),
which made this applicant pool significantly older (p < 0.01) than the general PLM
population (mean age 46.7 years ± 12.01 years). Overall, 333 (70%) of the applicants
were female (5 applicants did not report their gender), which made the proportion of
females applying to be on the panel higher than in the general PLM population
(54.7%). No information about ethnicity or education was collected.
Applicants reported 95 primary medical conditions in total. The most highly repre-
sented conditions (representing 61% of applicants) were multiple sclerosis (17%) and
fibromyalgia (15%). Appendix A: Table 1 presents the most frequent primary medical
conditions, which were reflective of the distribution of population sizes on the PLM
platform. The length of diagnosis ranged from 0 to 52 years across all conditions, with
an average of 11.62 (SD = 11.11) years, and a median of 7 years.
The level of prior experience with research varied but the majority of applicants re-
ported their experience focused on informal personal research they performed to learn
more about their condition (Appendix A: Table 2). In the sample, 29% had participated
in some type of research study, 16% had participated in a clinical trial, and 5% reported
having worked professionally as a researcher at the time of the application or in the
past.
Study 2
Applications were received from 33 participants including 18 PLM members and 15
individuals outside of PLM. Among PLM members, 8 (26%) were women and mean
age of all PLM members was 48 ± 14 years (range 26–87 years). Patients from outside
of PLM did not declare their age and gender. No additional demographic information
was collected.
In total, 33 applications were reviewed for clarity and specificity of idea along with
whether the disease condition was strongly represented within the PLM patient popula-
tion. Three applicants were selected for phone interviews and were invited to continue
with the process; only one applicant accepted the project and began the next steps of
developing the patient-reported outcome measure.
Content analysis
Study 1
The exploratory content analysis revealed four themes reflecting key reasons for PLM
members’ motivation to participate in the advisory panel and the research process.
Many applicants did not clearly explain their reason to participate or for their interest
in research and these responses were categorized as ‘Unclassified’. The responses were
read until the exhaustion of sources, i.e., when no new knowledge was forthcoming.
The saturation point was reached after 60 applications; the researcher read 5 more
applications to confirm that no new themes emerged. In total, 65 applications were
reviewed.
The first theme that emerged revolved around being an equal partner in doctor-
patient communications. One response, in particular, was that “I appreciate having a
doctor who treats me as a partner in this process of learning and treatment [of] my
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health challenges and who is willing to learn from me as well.” A majority of the
members of the advisory board expressed a desire to be treated as equal partners by
doctors and researchers. Patients reported feeling their healthcare providers often
neglected their voice. They wanted medical researchers and providers see their
situation in its entirety, rather than be focused on the single disease.
The second theme was centered around the patient’s desire to understand the
cause(s) and nature of their disease. For example, one response was “understanding
and pinpointing what causes multiple sclerosis and how to prevent people from getting
it.” Although some of the other themes contributed to motivation, the most explicitly
listed reason for motivation was to understand the cause of disease.
A third theme involved influencing the general approach of healthcare, specifically,
the patient’s desire for more effective communication about their condition from their
healthcare providers. One patient’s response was that “information provided in a way
that I can understand, in my own language and culture, geared towards my level of
health literacy would be a good start.” Many patients focused on ways to change how
healthcare providers and researchers interact with patients. Although patients acknow-
ledge they may have the same diagnosis as someone else, they wanted doctors to
approach them as individuals, understanding that what might serve as an appropriate
treatment for one patient may not work for another.
The fourth theme was centered around participation in decision making. One
patient’s response was “The obvious perspective is that patients should have some
voice in decisions regarding what research should be conducted, what the partici-
pants in research should be expected to do, how participants in research should
be selected, and how results of research should be communicated.” Patients felt
they had an important voice in all aspects of care and research. They voiced the
need for active inclusion in order to know where to start in terms of finding in-
formation and learning how to be involved in their own health care decisions.
Some patients reported they take a strong advocacy role in their condition
and want to help others communicate with healthcare providers. Frequencies of
each theme as they appeared in the sample of applications are presented in
Appendix A: Table 3.
Study 2
The exploratory content analysis of the responses in all applications from patients
within the PLM community and those outside the PLM community revealed the
occurrence of five themes reflecting the key reasons for patients’ interest in partici-
pating in a patient-led PRO measure development project. Applications lacking
consistent information about the patient’s interest were categorized as “incomplete
information.”
The first theme revolved around healthcare planning needs. One applicant’s response,
in particular, was that “The measure would be used in primary care practices in planning
for the youth's transition to the adult health care system.” The majority of applicants
suggested ideas for measurements that would be useful for the healthcare planning needs
of a specific population. The measure was not intended for the patient to use themselves
for ongoing monitoring of symptoms but rather for a healthcare provider to use for
management and planning of a patient’s condition.
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The second theme involved treatment outcomes. One particular response was “I want
to measure the effectiveness of a mind-body, touch based intervention such as therapeutic
massage for chronic pain.”, while another suggested “A survey (either questionnaire or by
email or phone contact), to determine how UVB-NB [Ultraviolet B-Narrowband] was
implemented in the treatment plan for psoriasis.” Applicants were interested in research
directed towards analyzing the effectiveness of an intervention, such as massage or an
electro-stimulator device, for treating chronic pain, for example. They also were interested
in understanding disease outcomes related to treatments for disease.
The third theme involved issues of symptom assessment. One applicant responded by
“I would like new standards for measuring pain.” Twelve percent of the applicants
proposed ideas for developing new ways to measure symptoms. These applicants
described a symptom or set of symptoms of interest and associated them with a condi-
tion of interest.
A fourth theme was a desire to understand the cause of disease, as expressed in one
applicant’s response:
“Dietary contributions to kidney stone formation in young adult females (20–35
years).” Fifteen percent of the proposed ideas were about understanding the cause of a
certain disease or new diagnostic measures to better characterize the disease. These
ideas ranged from questioning patient history to understanding exposures or identify-
ing biomarkers indicative of disease.
The fifth and final theme was making the patient the center of care. One applicant
responded with “All patients whose interest is participating more with physicians in a
meaningful way, getting results more effectively and efficiently, those wanting control over
their own data.” Under this umbrella, applicants focused on concepts that were essential
to making patients the center of care, whether it was giving them a tool to communicate
with providers or asking them about their satisfaction with care. Frequencies of each theme
as they appeared in the sample of applications are presented in Appendix A: Table 4.
Discussion
This paper describes two independent research projects both of which aimed to determine
patients’ motivations for being involved in research design and to understand their percep-
tions of current research practices. A patient’s desire to be involved in the research process
has been shown to increase their involvement in healthcare and research [16]. Patients can
be involved in their own healthcare decisions in various ways, including providing input on
treatments, symptoms, or other important aspects of their condition to measure. Addition-
ally, patients provide unique insight into their needs that can help drive the focus of
research. Some researchers have started to develop training materials for patients and
researchers and by sharing these materials with other researchers and receiving feedback
from patients, a standardized set of training materials can be created as a best practice when
involving patients in research [17]. Previous studies that involved patients into the research
process also emphasized the need to enhance communication to secure effective patient
participation in the research process [10, 18]. To receive the most valuable impact from
patients engaged in research, researchers and clinicians should make an effort to adequately
and transparently describe the research goal and the conceptual framework.
In our first study (Study 1), we demonstrated that patients are, indeed, motivated to par-
ticipate in healthcare and research and for various reasons. Some patients were mostly
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motivated to figure out the underlying mechanisms of their disease and wanted to engage
with researchers on this topic. As previously shown in the literature, this desire for under-
standing of disease is central for patients [19]. Other patients noted there were opportun-
ities for educating and empowering the patient population to speak up and demand to be
included in the decision-making process in healthcare. Many felt they needed to receive
more focused and individualized care that acknowledged how they are different from those
around them. This reflects the same need for individualized and carefully targeted care
previously emphasized in the literature [20].
Furthermore, patients wanted to become more empowered in issues surrounding their
own healthcare but emphasized a need to receive support from healthcare professionals in
order to be able to contribute effectively. There were some patients who may be able to em-
power others who do not feel as capable of making their voice heard. Previous literature con-
firms this sentiment as ‘empowered, engaged e-patients are a growing social movement’ [21].
Our second study (Study 2) was comprised of both PLM members and non-PLM
patients with a goal to discover the key reasons for the patients’ interest in participating in
patient-led PRO measurement development. Although many of the applicants presented
interesting ideas or demonstrated a concept important to research, the majority of these
were deemed not viable for developing a PRO measure by a psychometrician (MH). In
addition to the applications with incomplete information, some applications recom-
mended an assessment of an intervention or a way to determine biomarkers to reveal the
underlying cause of disease, which were outside the scope of this patient-led PRO project;
therefore, the patients who suggested them were not invited to proceed further.
The results of Study 2 revealed significant interest in PRO development across a broad
set of topics. Although patients frequently had a difficult time stating what they wanted to
measure in a way that would be appropriate for a PRO, many of them were capable of
articulating their area of interest. Patients demonstrated a desire for individualized and
focused measures specific to their disease. Although in the scope of the given research we
were unable to elaborate on and further process many applications, the applicant who
worked on the patient-led project was able to point out gaps that could help researchers
tailor a PRO measure to better fit her condition, as was demonstrated in previous literature
[9]. In an earlier study, a patient living with ALS led the development of modifications to a
widely-used existing PRO that suffered from a floor effect, meaning many subjects scored at
the bottom of the measure [22]. Therefore, the measure was insensitive to change in
patients with the most advanced stages of ALS [3]. By collaborating with researchers, this
patient was able to identify and validate new PRO items, which are now in use by the wider
research community [3, 9]. In a separate example, researchers examining patient involve-
ment in the Outcome Measures in Rheumatology (OMERACT) conferences determined
patient involvement in the conferences impacted the creation of outcome measures. During
these conferences, patients have presented new domains important to their experience and
influenced the development of core outcome sets [23].
Limitations existed in both of the studies. First, we acknowledge that the data
analyzed in both studies was not collected to address the specific research questions, i.e.,
patients’ motivation to take part in research and patients’ perspective of the current re-
search practice. In both studies, we conducted a secondary analysis of data primarily col-
lected for different purposes. The advantage of this analysis is that patients expressed
their motivation and perspective spontaneously. On the other hand, the questions posed
Bradley et al. Research Involvement and Engagement  (2016) 2:33 Page 9 of 15
to the applicants as part of the process pre-determined the permitted range of responses
revealed by the content analysis. Therefore, the results of the studies should be interpreted
with caution and used to inform future studies on the topic.
Limitations specific to Study 2 include the fact that no further information was
captured from individuals outside the PLM community regarding their source of infor-
mation about the study. Furthermore, demographic information was not captured from
applicants. Although this does not affect validity of the results, obtaining this informa-
tion in the future may enhance our understanding of the patient population interested
in research involvement. Separately, another limitation is some patients might view the
invitation as being complex and decide against applying thinking the skillset required is
higher than their expertise. The researchers developed open-ended questions in order
to give patients an opportunity to share their ideas without imposing any specific
research topics. However, looking back at the findings, proposing specific topics to
patients may be a more accessible and effective way to involve patients. Future programs
that would target involving patients in the PRO development process should build upon
the experience reported in this study. For example, the invitation should explain more
specifically about the requirements for PRO development and avoid the use of scientific
or technical language, which may not be clear to applicants. Although no specific skills or
training are required from the patients to be involved, patients would benefit from more
complete information about the scope of PRO measurements, including what can and
cannot be measured using PROs. Ideally, the invitation message should be structured in a
way to prevent patients from sending incomplete, irrelevant, or excessive information.
Other limitations are mostly related to the sample selection and data analysis method-
ology. An important limitation for both studies is representativeness of the patient popu-
lation. Although the PLM group is large in number, it is overrepresented by specific
disease types and conditions (e.g., neurological disease, such as ALS or multiple sclerosis).
In addition, members of the PLM community tend to be more active and more interested
in research than patients in general. They also tend to be higher education and are more
likely to be white and to be females. This implies the results of the study should not be
directly and immediately generalized upon the general patient population. Instead, they
should be perceived as an illustration of patient-oriented approach that reveals important
pros and cons of patient involvement, identifying some challenges that may be encoun-
tered and benefits that can be achieved. More studies should be conducted to develop the
best practice of engaging patients into the process of health care in general and PRO de-
velopment in particular. Additionally, the patients who responded to our applications
likely represent the most motivated patients. These patients may not be representative of
the activation levels of the general patient population. However, there is no reason to as-
sume their disease experience is substantially different from others with their condition.
Including the most active patients in research provides a foundation for increasing patient
involvement overall. As more patients realize clinicians and researchers are willing to hear
their voice, they are more likely to be involved.
From the methodological perspective, the current studies did not use a formal and sys-
tematic means of qualitative analysis. In both studies, a single rater was mostly responsible
in the coding of responses and consulted with an external rater as necessary. Additionally,
only one theme was assigned to each response, which was intended to focus on the key
motivations to participate in research since the questions were not specifically designed
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for this purpose. We recommend future studies that are specifically developed for this
purpose use several raters and qualitative software to confirm our findings. Future studies
should also evaluate the factors that may enhance patient involvement in research outside
of an online forum such as patient advocacy programs and training [24, 25].
Conclusion
The breadth of information found in qualitative review of the applications was extensive
and indicated there should be more efforts to involve patients. As shown through each
study, involving patients in research is a promising area and should continue to be evalu-
ated. The themes revealed patients are most interested in areas of research directly applic-
able to their individual condition and cause of disease. Additionally, patients new to being
involved in research need to be properly paired with researchers or patients with previous
research experience to receive support. Finally, researchers looking to involve patients
should be mindful of language used to limit scientific terminology and encourage patients
to share what is most important. Next steps in patient involvement should focus on
methods for continuous involvement to limit the burden on both patient and researcher
while leading to insights able to be incorporated into research.
Appendix A
Table 1 Most frequent (N = 10) primary conditions among advisory panel applicants
Primary condition Frequency Percent (%)
Multiple Sclerosis 81 16.80
Fibromyalgia 70 14.52
Parkinson’s Disease 52 10.79
Epilepsy 26 5.39
Rheumatoid Arthritis (RA) 19 3.94
Type 2 Diabetes 17 3.53
Amyotrophic Lateral Sclerosis (ALS) 15 3.11
Major Depressive Disorder 15 3.11




Clinical trial participant 16%
Professional researcher 5%
Table 3 Frequency of themes in the analyzed sample of advisory panel applications
Theme Frequency (%)
Understanding the causes and nature of the disease 18 (28%)
Influencing the general approach of healthcare 17 (26%)
Participating in decision making (having their voice heard) 12 (18%)
Being an equal partner in doctor-patient communication 8 (12%)
Unclassified 10 (15%)
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Appendix B
Advisory panel invitation message
I'm really excited to announce that we’re forming our very first team of patient advisors
at PatientsLikeMe. We’re looking for 6–12 people for the first year—and I think you
could be one of them!
This year, the team will be helping to make research more patient-centric. Since
you’re someone who is interested in research, it’s clear you’re as passionate as we are
about bringing the patient voice to research efforts. That’s why I’m extending an
invitation to you to apply to be on the 2014 team of advisors.
No formal science training is required to be an advisor — your “expertise” is the
experience you already have of being a patient. As an advisor, you will work with other
team members on initiatives such as:
Creating a “guide” that highlights new standards for researchers to better engage with
patients like you
Giving regular feedback to researchers on how their work can be more beneficial to
patients
You can apply to be an advisor here [link to application]. Applications are due by
April 15.
I’m really excited about this new opportunity and the impact it can have. I hope to
read your application soon!
Advisory panel application form
 Have you ever volunteered or worked with health-related organizations, research
associations, or advocacy groups? (If yes, please tell us what you did and why it
was, or was not, satisfying).
 What has been your experience with research? This includes participation in
studies (such as clinical trials), doing research on your own or professionally, or as
consumer/reader of research.
 What does patient-centeredness (in healthcare and/or research) mean to you?
 In your opinion, what is the most important research question that needs to be
addressed in order to better understand your condition?
 What are the barriers to undertaking this research question? How would you
address these barriers?
 Is there anything else you’d like to tell us about yourself?
Table 4 Frequency of themes in the analyzed sample of patient-led project applications
Theme Frequency (%)
Healthcare planning needs 8 (24%)
Treatment outcomes 6 (18%)
Symptom assessment 4 (12%)
Understanding disease 5 (15%)
Patient focused care 2 (6%)
Incomplete information 8 (24%)
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Appendix C
Patient-led PRO development project invitation message
Now YOU can lead the next research project on ORE
Do you have an idea for creating a better way to measure disease? If so, we’d love to
work with you!
We’ve just opened up ORE to patient-led research initiatives, so that you can develop,
test and validate new measures. It’s a whole new way to think about medicine. That’s
because health measures are typically developed by doctors and scientists, people who
aren’t necessarily living with the disease. So, their measures don’t always assess health
or quality of life in way that matter most to you – the patients.
Interested?
We’re supporting just two patient led projects this year, so if you’re interested, apply
now! Start by answering five questions about what you want to measure [link to
application].
Patient-led PRO development project application
 What do you want to measure? Is it about symptoms, or pain, or satisfaction
with treatment, for example? It’s best to narrow down your idea to one short
sentence, and to be very specific.
 Why do you want to develop a PRO measure? Think about why it’s important
to you, how useful it would be, and to whom. Have you talked to other patients
about their experience? When you can clearly articulate who the measure would
most benefit and why, you’ll be clearer about how to create it.
 Who do you want to test your measure with? Adults with a chronic condition
or women with MS are two examples of populations you could survey.
 How will your measure be used? Who will ultimately use it, when, and how
often?
 Are there any other similar measures? Take some time to review the scientific
literature. That’s part of the instrument development process and helps you learn
about the topic, develop your own opinion based on previous research, and build
on work that has been already done.
 What are the development stages for your instrument? They can include
concept elicitation, cognitive interviews, test and re-test phase, and a follow up
phase. Depending on your project goals, you may incorporate all or only some of
these stages.
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